HC Wainwright Reiterates Buy Rating for Ocular Therapeutix
HC Wainwright maintains its buy rating for Ocular Therapeutix with a $25 price target, a 147.16% upside from the current price.
Key Points
- HC Wainwright reiterated its buy rating for Ocular Therapeutix, Inc. (OCUL) with a $25 price target on June 18, 2026.
- HC Wainwright's $25 price target implies 147.16% upside from Ocular Therapeutix, Inc.'s ($OCUL) current $10.12 share price.
- Shares of Ocular Therapeutix are trading near $9.64, with a market cap of approximately $2.11 billion and a 52-week range between $6.23 and $16.44.
- Insiders including Adrienne Graves and CFO Jason Robins made notable stock purchases on June 10, 2026.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
HC Wainwright has reiterated its buy rating for Ocular Therapeutix, Inc. (NasdaqGM: OCUL) with a price target of $25. This rating update was provided by analyst Yi Chen on June 18, 2026. The stock is currently trading around $9.64.
Ocular Therapeutix, Inc. Stock Down 2.4%
Shares of Ocular Therapeutix are trading near $9.64. The company, which operates in the biotechnology sector, has a market capitalization of about $2.11 billion. Although it is not currently profitable, Ocular Therapeutix has a forward P/E ratio that is not meaningful due to negative earnings. The stock has experienced a 52-week low of $6.23 and a high of $16.44. Its 50-day moving average is approximately $9.00, while the 200-day moving average is around $10.53. The company maintains a strong liquidity position with a current ratio of 14.81 and a quick ratio of 14.49.
$OCUL price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Recent Earnings
Ocular Therapeutix reported revenue of $52.04 million, showing a slight growth of 0.8%. However, the company currently has a negative return on equity of -68.55% and a net margin of 0.0%. The next earnings report is expected on August 5, 2026.
Insider Buying and Selling at Ocular Therapeutix, Inc.
On June 10, 2026, several insiders, including Adrienne Graves and Chief Financial Officer Jason Robins, purchased shares of Ocular Therapeutix. Graves acquired 44,000 shares, while Robins bought 14,024 shares. Other insiders, such as Seung Suh Hong and Richard Lindstrom, also made notable purchases on the same day.
Analysts Set New Price Targets
On June 18, 2026, HC Wainwright reiterated its buy rating for Ocular Therapeutix with a $25 price target. Baird also maintained a buy rating with a target of $30. RBC Capital had earlier reiterated a buy rating with a $30 target on May 6, 2026. The overall analyst consensus for Ocular Therapeutix is a strong buy, with a mean price target of $26 based on 11 analyst opinions.
About Ocular Therapeutix
Ocular Therapeutix, Inc. is a biopharmaceutical company based in Bedford, Massachusetts, specializing in therapies for retinal diseases and other eye conditions. The company uses its bioresorbable hydrogel-based formulation technology to develop products like DEXTENZA, a dexamethasone ophthalmic insert for post-surgical inflammation and pain, and AXPAXLI, an axitinib intravitreal hydrogel for treating eye diseases. Led by CEO Dr. Pravin U. Dugel, the company was founded in 2006 and employs around 325 people.
Bottom Line
HC Wainwright's reaffirmation of a buy rating with a $25 target reflects continued confidence in Ocular Therapeutix's potential. Investors typically watch these ratings closely, but it's important to remember that this analysis is based on past data and may not represent current market conditions. As always, 13F filings and analyst ratings like these are backward-looking.
Get Ocular Therapeutix, Inc. alerts
New 13F filings, insider trades, and analyst moves on $OCUL, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.